160 related articles for article (PubMed ID: 21426562)
1. Economic burden of vulvar and vaginal intraepithelial neoplasia: retrospective cost study at a German dysplasia centre.
Hampl M; Huppertz E; Schulz-Holstege O; Kok P; Schmitter S
BMC Infect Dis; 2011 Mar; 11():73. PubMed ID: 21426562
[TBL] [Abstract][Full Text] [Related]
2. Cost-consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: the potential impact of different cross-protection profiles.
Capri S; Gasparini R; Panatto D; Demarteau N
Gynecol Oncol; 2011 Jun; 121(3):514-21. PubMed ID: 21334734
[TBL] [Abstract][Full Text] [Related]
3. Economic burden associated with the management of cervical cancer, cervical dysplasia and genital warts in Belgium.
Annemans L; Rémy V; Lamure E; Spaepen E; Lamotte M; Muchada JP; Largeron N
J Med Econ; 2008; 11(1):135-50. PubMed ID: 19450115
[TBL] [Abstract][Full Text] [Related]
4. Healthcare resource use and costs associated with cervical, vaginal and vulvar cancers in a large U.S. health plan.
Insinga RP; Ye X; Singhal PK; Carides GW
Gynecol Oncol; 2008 Nov; 111(2):188-96. PubMed ID: 18757080
[TBL] [Abstract][Full Text] [Related]
5. Mean medical costs associated with vaginal and vulvar cancers for commercially insured patients in the United States and Texas.
Fu S; Lairson DR; Chan W; Wu CF; Ramondetta L
Gynecol Oncol; 2018 Feb; 148(2):342-348. PubMed ID: 29274828
[TBL] [Abstract][Full Text] [Related]
6. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature.
Insinga RP; Dasbach EJ; Elbasha EH
Pharmacoeconomics; 2005; 23(11):1107-22. PubMed ID: 16277547
[TBL] [Abstract][Full Text] [Related]
7. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.
; Dillner J; Kjaer SK; Wheeler CM; Sigurdsson K; Iversen OE; Hernandez-Avila M; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch FX; Joura EA; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Maansson R; Lu S; Vuocolo S; Hesley TM; Barr E; Haupt R
BMJ; 2010 Jul; 341():c3493. PubMed ID: 20647284
[TBL] [Abstract][Full Text] [Related]
8. Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions.
Serrano B; de Sanjosé S; Tous S; Quiros B; Muñoz N; Bosch X; Alemany L
Eur J Cancer; 2015 Sep; 51(13):1732-41. PubMed ID: 26121913
[TBL] [Abstract][Full Text] [Related]
9. Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and pre-invasive neoplasia: establishing the baseline for surveillance.
Nygård M; Hansen BT; Dillner J; Munk C; Oddsson K; Tryggvadottir L; Hortlund M; Liaw KL; Dasbach EJ; Kjær SK
PLoS One; 2014; 9(2):e88323. PubMed ID: 24505474
[TBL] [Abstract][Full Text] [Related]
10. The economic burden of human papillomavirus-related precancers and cancers in Sweden.
Östensson E; Silfverschiöld M; Greiff L; Asciutto C; Wennerberg J; Lydrup ML; Håkansson U; Sparén P; Borgfeldt C
PLoS One; 2017; 12(6):e0179520. PubMed ID: 28651012
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus type-distribution in vulvar and vaginal cancers and their associated precursors.
Smith JS; Backes DM; Hoots BE; Kurman RJ; Pimenta JM
Obstet Gynecol; 2009 Apr; 113(4):917-924. PubMed ID: 19305339
[TBL] [Abstract][Full Text] [Related]
12. Systematic review and evidence synthesis of non-cervical human papillomavirus-related disease health system costs and quality of life estimates.
Ong KJ; Checchi M; Burns L; Pavitt C; Postma MJ; Jit M
Sex Transm Infect; 2019 Feb; 95(1):28-35. PubMed ID: 30674687
[TBL] [Abstract][Full Text] [Related]
13. Association of human papillomavirus with vulvar and vaginal intraepithelial disease: opportunities for prevention.
Pearson JM; Feltman RS; Twiggs LB
Womens Health (Lond); 2008 Mar; 4(2):143-50. PubMed ID: 19072516
[TBL] [Abstract][Full Text] [Related]
14. The annual costs associated with human papillomavirus types 6, 11, 16, and 18 infections in Finland.
Herse F; Reissell E
Scand J Infect Dis; 2011 Mar; 43(3):209-15. PubMed ID: 21171829
[TBL] [Abstract][Full Text] [Related]
15. Detection of Human Papillomavirus Infection in Patients with Vaginal Intraepithelial Neoplasia.
Lamos C; Mihaljevic C; Aulmann S; Bruckner T; Domschke C; Wallwiener M; Paringer C; Fluhr H; Schott S; Dinkic C; Brucker J; Golatta M; Gensthaler L; Eichbaum M; Sohn C; Rom J
PLoS One; 2016; 11(12):e0167386. PubMed ID: 27907089
[TBL] [Abstract][Full Text] [Related]
16. Vulvar and vaginal HPV disease.
Nelson EL; Stockdale CK
Obstet Gynecol Clin North Am; 2013 Jun; 40(2):359-76. PubMed ID: 23732036
[TBL] [Abstract][Full Text] [Related]
17. The Direct Medical Costs of Diseases Associated with Human Papillomavirus Infection in Manitoba, Canada.
Righolt CH; Pabla G; Mahmud SM
Appl Health Econ Health Policy; 2018 Apr; 16(2):195-205. PubMed ID: 29299769
[TBL] [Abstract][Full Text] [Related]
18. The economic burden of noncervical human papillomavirus disease in the United States.
Hu D; Goldie S
Am J Obstet Gynecol; 2008 May; 198(5):500.e1-7. PubMed ID: 18455524
[TBL] [Abstract][Full Text] [Related]
19. Incidence and cost of anal, penile, vaginal and vulvar cancer in Denmark.
Olsen J; Jørgensen TR; Kofoed K; Larsen HK
BMC Public Health; 2012 Dec; 12():1082. PubMed ID: 23244352
[TBL] [Abstract][Full Text] [Related]
20. Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia.
Baldwin PJ; van der Burg SH; Boswell CM; Offringa R; Hickling JK; Dobson J; Roberts JS; Latimer JA; Moseley RP; Coleman N; Stanley MA; Sterling JC
Clin Cancer Res; 2003 Nov; 9(14):5205-13. PubMed ID: 14614000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]